2. Search Result
Search Result
Results for "

v-Abl

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

4

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-G0017
    N-Desmethyl imatinib

    Norimatinib; Imatinib metabolite N-Desmethyl imatinib

    		 Drug Metabolite Others
    N-Desmethyl imatinib (Norimatinib) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .
    N-Desmethyl imatinib
  • HY-W062835
    CGP77675

    		Src Cancer
    CGP77675 is an orally active and potent inhibitor of Src family kinases. CGP77675 inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50s of 5-20 and 40 nM, respectively), and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC50s of 5-20, 40, 20, 150, 1000, 310, and 290 nM, respectively. Anticancer activity .
    CGP77675
  • HY-G0017A
    N-Desmethyl imatinib mesylate

    Norimatinib mesylate; Imatinib metabolite N-Desmethyl imatinib mesylate

    		 Drug Metabolite Others
    N-Desmethyl imatinib mesylate (Norimatinib mesylate) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .
    N-Desmethyl imatinib mesylate
  • HY-G0017S1
    N-Desmethyl imatinib-d4

    Norimatinib-d4; Imatinib metabolite N-Desmethyl imatinib-d4

    		 Isotope-Labeled Compounds Others
    N-Desmethyl imatinib-d4 is the deuterium-labeled N-Desmethyl imatinib (HY-G0017). N-Desmethyl imatinib-d4 (Norimatinib) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .
    N-Desmethyl imatinib-d4
  • HY-W062835A
    CGP77675 hydrate

    		Src Cancer
    CGP77675 hydrate is an orally active and potent inhibitor of Src family kinases. CGP77675 hydrate inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50s of 5-20 and 40 nM, respectively),and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC50s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity .
    CGP77675 hydrate
  • HY-15463S
    Imatinib-d8
    1 Publications Verification

    STI571-d8; CGP-57148B-d8

    		 Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib-d8 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].
    Imatinib-d8
  • HY-15463S1
    Imatinib-d4

    STI571 d4; CGP-57148B d4

    		 Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib-d4 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].
    Imatinib-d4
  • HY-15463
    Imatinib
    70+ Cited Publications

    STI571; CGP-57148B

    		 Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
    Imatinib
  • HY-15463S2
    Imatinib-d3 hydrochloride

    STI571-d3 hydrochloride; CGP-57148B-d3 hydrochloride

    		 Autophagy Bcr-Abl c-Kit SARS-CoV PDGFR Cancer
    Imatinib-d3 (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.
    Imatinib-d3 hydrochloride
  • HY-131275
    Imatinib Impurity E

    		Drug Metabolite Others
    Imatinib Impurity E is the impurity of Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
    Imatinib Impurity E
  • HY-15463R
    Imatinib (Standard)

    		Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib (Standard) is the analytical standard of Imatinib. This product is intended for research and analytical applications. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
    Imatinib (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: